Tigecycline: Difference between revisions
(Text replacement - "*Diarrhea" to "*Diarrhea") |
ClaireLewis (talk | contribs) |
||
(3 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: [[Glycylcycline]] ([[Tetracyclines]]) | *Type: [[Glycylcycline]] ([[Tetracyclines]]) | ||
*Dosage Forms: | *Dosage Forms: IV | ||
*Common Trade Names: Tygacil | *Common Trade Names: Tygacil | ||
==Adult Dosing== | ==Adult Dosing== | ||
=== | ===Intra-Abdominal Infections=== | ||
* | *50mg IV q12h x5-14 days | ||
**Start: 100mg IV x1 | |||
===Skin Infections, complicated=== | |||
*50mg IV q12h x5-14 days | |||
**Start: 100mg IV x1 | |||
===[[Pneumonia]], Community acquired=== | |||
*50mg IV q12h for at least 5 days | |||
**Start 100mg IV x1 | |||
**May D/C after 5 days if afebrile 48-72h | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
=== | ===Intra-abdominal Infections=== | ||
* | *8-11yo | ||
**1.2 mg/kg IV q12h | |||
**Max: 50 mg/12h | |||
*12-17 yo | |||
**50mg IV 112h | |||
===Skin Infections, complicated=== | |||
*8-11yo | |||
**1.2 mg/kg IV q12h | |||
**Max: 50 mg/12h | |||
*12-17 yo | |||
**50mg IV 112h | |||
===[[Pneumonia]], Community Acquired=== | |||
*8-11yo | |||
**1.2 mg/kg IV q12h | |||
**Max: 50 mg/12h | |||
*12-17 yo | |||
**50mg IV 112h | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Drug rating in pregnancy]]: | *[[Drug Ratings in Pregnancy|Drug rating in pregnancy]]: D | ||
*[[Lactation_risk_categories|Lactation risk category]]: Possibly Unsafe; consider alternatives | *[[Lactation_risk_categories|Lactation risk category]]: Possibly Unsafe; consider alternatives | ||
*Renal Dosing | *Renal Dosing | ||
**Adult: | **Adult: No adjustment | ||
**Pediatric: | **Pediatric: No adjustment | ||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult: | **Adult: | ||
***Child-Pugh Class C: Decrease maintenance dose 50% | |||
**Pediatric: | **Pediatric: | ||
* | ***Not defined, but may be required. See adult dosing. | ||
==Contraindications== | ==Contraindications== | ||
Line 27: | Line 52: | ||
*Pregnancy | *Pregnancy | ||
*Age <8 years | *Age <8 years | ||
*Hospital-acquired pneumonia | |||
*Diabetic foot infection | |||
*Caution: | *Caution: | ||
**Child bearing potential | **Child bearing potential | ||
** | **Hepatic impairment | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
Line 52: | Line 79: | ||
*Jarisch-Herxheimer reaction | *Jarisch-Herxheimer reaction | ||
*Fetal harm | *Fetal harm | ||
===Common=== | ===Common=== | ||
Line 66: | Line 93: | ||
*Skin discoloration | *Skin discoloration | ||
*Elevated BUN | *Elevated BUN | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: Unknown | ||
*Metabolism: | *Metabolism: Minimal | ||
*Excretion: | *Excretion: Bile/feces - 59%; Urine 33% | ||
*Mechanism of Action: Bacteriostatic | *Mechanism of Action: Bacteriostatic | ||
Line 195: | Line 222: | ||
===Key=== | ===Key=== | ||
{{Template:Antibacterial Spectra Key}} | {{Template:Antibacterial Spectra Key}} | ||
==See Also== | ==See Also== | ||
*[[Antibiotics (Main)]] | *[[Antibiotics (Main)]] | ||
== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:ID]] |
Latest revision as of 23:01, 23 September 2019
General
- Type: Glycylcycline (Tetracyclines)
- Dosage Forms: IV
- Common Trade Names: Tygacil
Adult Dosing
Intra-Abdominal Infections
- 50mg IV q12h x5-14 days
- Start: 100mg IV x1
Skin Infections, complicated
- 50mg IV q12h x5-14 days
- Start: 100mg IV x1
Pneumonia, Community acquired
- 50mg IV q12h for at least 5 days
- Start 100mg IV x1
- May D/C after 5 days if afebrile 48-72h
Pediatric Dosing
Intra-abdominal Infections
- 8-11yo
- 1.2 mg/kg IV q12h
- Max: 50 mg/12h
- 12-17 yo
- 50mg IV 112h
Skin Infections, complicated
- 8-11yo
- 1.2 mg/kg IV q12h
- Max: 50 mg/12h
- 12-17 yo
- 50mg IV 112h
Pneumonia, Community Acquired
- 8-11yo
- 1.2 mg/kg IV q12h
- Max: 50 mg/12h
- 12-17 yo
- 50mg IV 112h
Special Populations
- Drug rating in pregnancy: D
- Lactation risk category: Possibly Unsafe; consider alternatives
- Renal Dosing
- Adult: No adjustment
- Pediatric: No adjustment
- Hepatic Dosing
- Adult:
- Child-Pugh Class C: Decrease maintenance dose 50%
- Pediatric:
- Not defined, but may be required. See adult dosing.
- Adult:
Contraindications
- Allergy to class/drug
- Pregnancy
- Age <8 years
- Hospital-acquired pneumonia
- Diabetic foot infection
- Caution:
- Child bearing potential
- Hepatic impairment
Adverse Reactions
Serious
- Tooth discoloration children <8 years old
- Photosensitivity
- Hypersensitivity reaction
- Skin reaction
- Vasculitis
- Pericarditis
- Autoimmune hepatitis
- Hepatotoxicity
- Nephrotoxicity
- Esophagitis/ulcer
- Pancreatitis
- Thrombocytopenia
- Neutropenia
- Hemolytic anemia
- Pseudotumor cerebri
- Bulging fontanelles
- Jarisch-Herxheimer reaction
- Fetal harm
Common
- Headache
- Nausea
- Dyspepsia
- Arthralgia
- Diarrhea
- Rash
- Dysmenorrhea
- Photosensitivity
- Vulvovaginal candidiasis
- Skin discoloration
- Elevated BUN
Pharmacology
- Half-life: Unknown
- Metabolism: Minimal
- Excretion: Bile/feces - 59%; Urine 33%
- Mechanism of Action: Bacteriostatic
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014